ExpreS2ion and NextGen enter a Joint Venture for accelerated development of new, improved vaccines and immune therapy
(WorldNews Denmark)

Hørsholm, Denmark, June 21, 2017 - Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (`ExpreS2ion`) has established a joint venture named AdaptVac ApS with NextGen Vaccines ApS (`NextGen`), a company recently formed by scientists from the University of Copenhagen. AdaptVac has a worldwide exclusive license to a new Plug-and-Play Virus Like Particle (VLP) technology, which enables accelerated development of efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. AdaptVac ApS The aim of the...